The information contained within this announcement is deemed to constitute inside information as stipulated under the retained EU law version of the Market Abuse Regulation (EU) No. 596/2014 (the "UK MAR") which is part of UK law by virtue of the European Union (Withdrawal) Act 2018. The information is disclosed in accordance with the Company's obligations under Article 17 of the UK MAR. Upon the publication of this announcement, this inside information is now considered to be in the public domain.
21 December 2023
Kropz Plc
("Kropz" or the "Company")
BNP loan facility agreement update
The Company is in the process of refinancing the BNP loan facility (outstanding amount US$ 15,000,000). BNP has extended its waiver period to 31 March 2024. A replacement loan is expected to be in place by the first quarter of 2024, before expiry of the facility.
The Company will provide further updates in due course.
For further information visit www.kropz.com or contact:
| Kropz Plc | Via Tavistock |
| Louis Loubser (CEO) | +44 (0) 207 920 3150 |
|
|
|
| Grant Thornton UK LLP | Nominated Adviser |
| Samantha Harrison Harrison Clarke Ciara Donnelly
| +44 (0) 20 7383 5100 |
|
| |
| Hannam & Partners | Broker |
| Andrew Chubb Ernest Bell | +44 (0) 20 7907 8500 |
|
|
|
| Tavistock | Financial PR & IR (UK) |
| Nick Elwes Jos Simson | +44 (0) 207 920 3150 kropz@tavistock.co.uk |
|
|
|
| R&A Strategic Communications | PR (South Africa) |
| Charmane Russell Marion Brower | +27 (0) 11 880 3924 charmane@rasc.co.za marion@rasc.co.za
|
About Kropz Plc
Kropz is an emerging African phosphate producer and developer with projects in South Africa and in the Republic of Congo. The vision of the Group is to become a leading independent phosphate rock producer and to develop into an integrated, mine-to-market plant nutrient company focusing on sub-Saharan Africa.
-ENDS-
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.